- Home
- MGNX vs COYA Comparison
MGNX vs COYA Comparison
Compare MGNX & COYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MGNX | COYA |
|---|---|---|
| Founded | 2000 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 112.6M | 126.6M |
| IPO Year | 2013 | 2022 |
Fundamental Metrics
Financial Performance| Metric | MGNX | COYA |
|---|---|---|
| Price | $1.80 | $4.59 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $3.20 | ★ $15.80 |
| AVG Volume (30 Days) | ★ 1.0M | 326.8K |
| Earning Date | 03-19-2026 | 03-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $127,626,000.00 | $3,987,706.00 |
| Revenue This Year | N/A | $70.00 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.99 | $3.94 |
| 52 Week High | $3.33 | $8.29 |
Technical Indicators
Market Signals| Indicator | MGNX | COYA |
|---|---|---|
| Relative Strength Index (RSI) | 59.00 | 39.91 |
| Support Level | $1.62 | $4.51 |
| Resistance Level | $1.89 | $4.82 |
| Average True Range (ATR) | 0.11 | 0.36 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 63.16 | 44.17 |
Price Performance
Historical ComparisonAbout MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
About COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.